Login to Your Account



ARE ALL PARPS CREATED EQUAL?

Abbvie phase III miss with veliparib puts wrinkle in PARP effort

By Marie Powers
News Editor

Friday, April 21, 2017

Veliparib, Abbvie Inc.'s only shot at the oral poly-ADP ribose polymerase (PARP) market, failed two key phase III tests, missing the primary endpoints in studies evaluating the agent in combination with carboplatin and paclitaxel in patients with squamous non-small-cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription